Prostate Health
BPH is near-universal with aging. PSA testing involves tradeoffs. Most prostate cancers are slow-growing. Understanding the nuances helps inform better decisions.
Prostate issues are common in aging men. The challenge is distinguishing what benefits from treatment from what may be better monitored. Most men with prostate cancer will die with it, not from it. Understanding when intervention helps—and when it may cause more harm than benefit—is essential for informed decision-making.
BPH: Benign Prostatic Hyperplasia
BPH (enlarged prostate) affects approximately 50% of men by 60 and a higher proportion by 80. It is not cancer, does not increase cancer risk, and often does not require treatment unless symptoms are bothersome.
BPH Prevalence by Age
Estimated percentage of men with histological BPH
Source: Berry et al., J Urol 1984; Roehrborn, Rev Urol 2005
🚿 Symptoms (LUTS)
- Obstructive: Weak stream, hesitancy, incomplete emptying, straining
- Irritative: Frequency, urgency, nocturia (waking to urinate)
- Progression is common but not inevitable
- Symptom severity doesn't correlate well with prostate size
- IPSS questionnaire can help assess severity
💊 Treatment Options
- Watchful waiting: Reasonable for mild symptoms
- Alpha-blockers: Tamsulosin, alfuzosin—relax smooth muscle; faster onset
- 5-ARIs: Finasteride, dutasteride—can shrink prostate; takes months
- Combination: Both classes may help for larger prostates
- Procedures: TURP, UroLift, laser—for more severe cases
PSA Testing: Understanding the Tradeoffs
Cancer Probability by PSA Level
Based on biopsy data from the Prostate Cancer Prevention Trial
Source: Thompson et al., NEJM 2004. Note: These are population-level probabilities; individual risk depends on multiple factors.
📊 Current Guideline Perspectives
- Ages 55-69: Guidelines recommend shared decision-making (discussing pros and cons)
- Higher risk: Black men, family history—earlier discussion may be appropriate
- Over 70: Routine screening generally not recommended
- PSA velocity: Rate of change over time may be informative
- PSA density: PSA relative to prostate volume adds context
⚖️ The Screening Discussion
- Screening finds many cancers that may never cause symptoms
- Treatment has potential side effects (ED, incontinence)
- For every life saved, studies suggest multiple men may be overtreated
- Active surveillance has changed the risk-benefit calculation
- The question is not just "to screen" but "what to do with results"
| PSA Level | Cancer Probability (approx) | High-Grade Cancer (approx) | Typical Considerations |
|---|---|---|---|
| <1.0 ng/mL | ~6% | ~1% | Recheck in 2-4 years if screening |
| 1.0-2.5 | ~10% | ~3% | Recheck in 1-2 years |
| 2.5-4.0 | ~17% | ~7% | MRI may be helpful; discuss biopsy |
| 4.0-10.0 | ~25% | ~15% | MRI + possible targeted biopsy often recommended |
| >10.0 | ~50% | ~35% | Biopsy generally recommended |
Prostate Cancer: Context Matters
📈 Risk Factors
- Age: Uncommon before 50; risk increases with age
- Race: Black men have ~2x incidence, often more aggressive disease
- Family history: ~2x risk with first-degree relative
- BRCA2 mutation: Associated with higher risk, more aggressive disease
- Lynch syndrome: Associated with increased risk
🎯 Grade Groups (Gleason)
- Group 1 (Gleason ≤6): Low risk—active surveillance often appropriate
- Group 2 (Gleason 3+4=7): Favorable intermediate—approach varies
- Group 3 (Gleason 4+3=7): Unfavorable intermediate—treatment often indicated
- Group 4-5 (Gleason 8-10): High/very high risk—treatment typically recommended
- Grade is generally more prognostic than PSA level
Active Surveillance: Monitoring with Intent to Treat
Active surveillance has become standard of care for appropriately selected low-risk prostate cancer. It involves regular monitoring with the goal of treating if and when the cancer shows signs of progression.
✅ Typically Good Candidates for AS
- Gleason Grade Group 1 (≤6)
- PSA <10 ng/mL
- T1-T2a stage (organ-confined)
- Limited tumor volume on biopsy
- Patient comfortable with monitoring approach
📋 Typical AS Protocol
- PSA every 3-6 months initially
- DRE every 6-12 months
- Repeat MRI at ~1 year, then periodically
- Repeat biopsy at 1 year, then every 2-5 years
- Trigger for treatment: grade progression or significant growth
✓ Questions to Consider Discussing with Your Doctor
📌 The Bottom Line
PSA Involves Tradeoffs
Screening finds cancers but also leads to overdiagnosis. Discuss benefits and harms with your doctor.
BPH Is Manageable
Common and annoying but not dangerous. Effective treatments exist if symptoms warrant.
Most PC Is Slow-Growing
Active surveillance is appropriate for many low-risk cancers. Aggressive treatment isn't always better.
Risk Varies by Person
Black men and those with family history may benefit from earlier, more careful evaluation.
Key Sources for This Page
- PSA and cancer probability: Thompson IM, et al. Prevalence of prostate cancer among men with PSA ≤4.0 ng/mL. N Engl J Med. 2004;350(22):2239-46.
- ProtecT trial (15-year outcomes): Hamdy FC, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547-1558.
- USPSTF recommendation: US Preventive Services Task Force. Screening for prostate cancer. JAMA. 2018;319(18):1901-1913.
- Active surveillance: Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82.